Read by QxMD icon Read

Thoracic Cancer

Yunkyoung Lee, Sojung Park, Woo Sung Kim, Jae Cheol Lee, Se Jin Jang, Jene Choi, Chang-Min Choi
BACKGROUND: This study was conducted to identify whether the presence of circulating tumor DNA (ctDNA) in plasma before treatment with EGFR-tyrosine kinase inhibitors (TKIs) is associated with clinical outcomes. METHODS: Fifty-seven pairs of tissues and plasma samples were obtained from patients with NSCLC adenocarcinoma harboring activating EGFR mutations before the administration of EGFR-TKI treatment. ctDNA mutation was identified using the PANAMutyper EGFR mutation kit...
July 10, 2018: Thoracic Cancer
Jin Kang, Hua-Jun Chen, Xu-Chao Zhang, Jian Su, Qing Zhou, Hai-Yan Tu, Zhen Wang, Bin-Chao Wang, Wen-Zhao Zhong, Xue-Ning Yang, Zhi-Hong Chen, Yan Ding, Xue Wu, Mei Wang, Jian-Gang Fu, Zhenfan Yang, Xian Zhang, Yang W Shao, Yi-Long Wu, Jin-Ji Yang
BACKGROUND: ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis. METHODS: Targeted next-generation sequencing (NGS) mutation profiling was performed on samples from 42 NSCLC patients confirmed positive for ALK rearrangements by fluorescence in situ hybridization or immunohistochemistry who experienced disease progression after crizotinib treatment...
July 6, 2018: Thoracic Cancer
Guihong Liu, Tao Chen, Ronghui Li, Li Zhu, Dingyi Liu, Zhenyu Ding
Squamous cancer (SqCC) of the lung has a poor prognosis. With the advent of immunotherapy, prognosis has tended to improve; however, pseudoprogression poses a challenge to the management of immunotherapy. Herein, we discuss the case of a 47-year-old heavy smoker with advanced SqCC. The patient had recurrent disease after initial successful control of the tumor by concurrent radiochemotherapy, together with ample pleural effusion. Pleural effusion was well controlled with systematic nivolumab and intra-thoracic recombinant endostatin; however with simultaneous deterioration of performance and tumor progression...
July 6, 2018: Thoracic Cancer
Ke Ma, Yong Yang, Shuai Wang, Xiaodong Yang, Tao Lu, Junjie Xi, Wei Jiang, Cheng Zhan, Yimeng Zhu, Qun Wang
BACKGROUND: The effect of neoadjuvant radiotherapy (NRT) was controversial in non-cervical esophageal cancer. The aim of this study was to identify which stage of non-cervical esophageal cancer would get benefit from NRT using propensity score matching (PSM) and survival analysis based on the Surveillance Epidemiology, and End Results (SEER) database. METHODS: A selection process was used for case screening from the SEER database. Seven baseline variables were included in PSM...
July 1, 2018: Thoracic Cancer
HanRan Wu, ChangQing Liu, MeiQing Xu, MingFa Guo, ShiBin Xu, MingRan Xie
BACKGROUND: The impact of the number of negative lymph nodes (LNs) on survival in patients with esophageal cancer remains a controversial issue. This study investigated the association between the number of resected LNs and the prognosis of patients with node-negative esophageal carcinoma. METHODS: A retrospective review was performed of the data of 429 patients who underwent esophagectomy with modern two-field lymphadenectomy for the treatment of esophageal cancer between January 1998 and December 2008...
June 28, 2018: Thoracic Cancer
Ying Zhu, Lei Fu, Wang Jing, Dong Guo, Li Kong, Jinming Yu
BACKGROUND: We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS: Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), objective response rate (ORR), and adverse events...
June 27, 2018: Thoracic Cancer
Yufei Wang, Ke Wang, Chunyan Guo, Zhanlin Guo
Congenital pulmonary arteriovenous fistulae occur as a result of abnormal blood vessel development in the lungs. Blood takes a short pass from the pulmonary artery to veins. Multiple pulmonary arteriovenous fistulae are a rare occurrence, especially when involving both lungs. Fistulae located at the edge are prone to rupture and bleeding. We discuss a case of a 15-year-old overweight male with multiple pulmonary arteriovenous fistulae successfully treated with wedge-shape excision via video-assisted thoracoscopic surgery...
June 23, 2018: Thoracic Cancer
Zhongling Zhu, Peng Chen, Zhao Yan
No abstract text is available yet for this article.
June 22, 2018: Thoracic Cancer
Shicheng Li, Xiao Sun, Shuncheng Miao, Tong Lu, Yuanyong Wang, Jia Liu, Wenjie Jiao
BACKGROUND: Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for cancer progression. METHODS: We examined differentially expressed circRNAs in LUAD and paired normal tissues using downloaded circRNA microarrays from the Gene Expression Omnibus...
June 22, 2018: Thoracic Cancer
Young Sik Park, Jinwoo Lee, Bhumsuk Keum, Byung-Mo Oh
The scientific evidence supporting pulmonary rehabilitation (PR) for lung cancer patients undergoing cytotoxic chemotherapy is accumulating; however, the feasibility of outpatient-based PR in these patients has not yet been evaluated in Korea. We conducted an eight-week outpatient-based PR feasibility study in a tertiary referral hospital setting. Patients with advanced lung cancer (non-small cell lung cancer IIIB-IV and small-cell lung cancer extensive disease) scheduled to undergo first-line cytotoxic chemotherapy underwent PR consisting of 60-minute sessions twice a week under the guidance and supervision of a physical therapist, for a total of eight weeks...
June 22, 2018: Thoracic Cancer
Lei Tuo, Sha Sha, Zhang Huayu, Ke Du
BACKGROUND: This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS: Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases. Publications relevant to P16INK4a gene promoter methylation in serum or bronchoalveolar fluid/sputum were screened and included in this meta-analysis...
June 21, 2018: Thoracic Cancer
Xiayi Lv, Jinlin Cao, Xiaona Dai, Aizemaiti Rusidanmu
BACKGROUND: Lung cancer in the right middle lobe has a poorer prognosis than tumors located in other lobes. The optimal surgical procedure for early-stage non-small cell lung cancer (NSCLC) in the right middle lobe has not yet been elucidated. The aim of this study was to compare survival rates after lobectomy and sublobar resection for early-stage right middle lobe NSCLC. METHODS: Patients who underwent lobectomy or sublobar resection for stage IA right middle lobe NSCLC tumors ≤ 2 cm between 2004 and 2014 were identified from the Surveillance, Epidemiology and End Results database of 18 registries...
June 21, 2018: Thoracic Cancer
Min Liu, Jie Ran, Jun Zhou
Kinesins are widely expressed, microtubule-dependent motors that play vital roles in microtubule-associated cellular activities, such as cell division and intracellular transport. Eg5, also known as kinesin-5 or kinesin spindle protein, is a member of the kinesin family that contributes to the formation and maintenance of the bipolar mitotic spindle during cell division. Small-molecule compounds that inhibit Eg5 activity have been shown to impair spindle assembly, block mitotic progression, and possess anti-cancer activity...
June 21, 2018: Thoracic Cancer
Peiliang Zhao, Wanpu Yan, Hao Fu, Yao Lin, Ke-Neng Chen
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer and most clinically curable patients are diagnosed with locally advanced disease. While the efficacy of preoperative treatment is relatively clear and well characterized, the effect of postoperative treatment, especially postoperative chemotherapy, remains controversial, and its role in the treatment strategy is obscure. We conducted an updated meta-analysis to include recent developments...
June 21, 2018: Thoracic Cancer
Hui Zhang, WeiJian Zhang, DeFeng Peng, JinHai Zhu
BACKGROUND: The study was conducted to investigate the short-term complications and prognostic factors in patients with esophagogastric junction adenocarcinoma (EGJA). METHODS: This retrospective study included 110 EGJA patients who underwent surgery from January 2010 to November 2012 at The First Affiliated Hospital of BengBu Medical College. The overall survival and short-term complications were analyzed according to the patients' clinical characteristics. RESULTS: The incidence of postoperative cardiopulmonary complications was significantly higher in patients with preoperative cardiopulmonary disease or elderly patients (P < 0...
June 21, 2018: Thoracic Cancer
Xin Li, Han Qi, Gou Qing, Ze Song, Lin Xie, Fei Cao, Xiaoming Chen, Weijun Fan
BACKGROUND: Although patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR-TKI therapy beyond focal progression, associated with microwave ablation. METHODS: Patients with metastatic EGFR-mutant NSCLC treated with EGFR-TKIs at our institutions from May 2012 to December 2017 were identified...
June 20, 2018: Thoracic Cancer
Dongdong Zhu, Peng Hong, Shengbin Chen, Yu Fan, Zhongyuan Zhang, Xiaochun Zhang, Wei Yu, Cheng Shen, Jie Jin
Lower posterior mediastinal tumors are traditionally excised by conventional thoracotomy or thoracoscopic approaches; however, use of the transdiaphragmatic retroperitoneoscopic approach for these tumors has rarely been reported. Herein, we report a case of a left lower posterior mediastinal paravertebral benign schwannoma in an adult male that was successfully treated with transdiaphragmatic retroperitoneoscopic surgery. The patient presented with no symptoms but had noticed a lesion in the left lower posterior mediastinum two months prior...
June 20, 2018: Thoracic Cancer
Xiaoyan Si, Shafei Wu, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Xuan Zeng, Li Zhang
BACKGROUND: This study was conducted to evaluate the efficacy and safety of nimotuzumab combined with chemotherapy as first-line therapy in advanced lung squamous cell carcinoma (LSCC), and to explore predictive biomarkers of the efficacy of nimotuzumab. METHODS: A retrospective study was conducted of patients with advanced LSCC administered nimotuzumab combined with chemotherapy as first-line therapy from June 2012 to December 2016 at the Department of Respiratory Medicine, Peking Union Medical College Hospital...
June 19, 2018: Thoracic Cancer
Haiyan Xu, Fei Xu, Wenjie Zhu, Jianming Ying, Yan Wang
BACKGROUND: Platinum-based chemotherapy is the standard first-line treatment for patients with advanced pan-negative non-squamous (non-Sq) non-small cell lung cancer (NSCLC). However, it is unknown which chemotherapy regimen confers the greatest benefit in such patients. This study explored which chemotherapy regimens were advantageous in non-Sq NSCLC patients. METHODS: A retrospective study was conducted on 114 patients with advanced non-Sq NSCLC using platinum-based chemotherapy in a first-line setting between January 2013 and December 2015...
June 19, 2018: Thoracic Cancer
Haitao Zhou, Xiaozheng Kang, Liang Dai, Wanpu Yan, Yongbo Yang, Yao Lin, Ke-Neng Chen
BACKGROUND: The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS: All cases of lung cancer included in our prospective database between January 2000 and July 2015 were retrospectively reviewed. The oncological efficacy endpoints for synchronous and metachronous MPR were five-year overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) rates after the second surgery...
June 19, 2018: Thoracic Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"